Epigenetic therapy and chemosensitization in solid malignancy

Cancer Treatment Reviews

Volumn 55, Issue , 2017, Pages 200-208

  Ronnekleiv Kelly, Sean M ^a   Sharma, Anup ^a   Ahuja, Nita ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Chemosensitization; Epigenetic therapy; Epigenetics; Solid tumors

Indexed keywords

2 METHOXY N (1,2,3,4 TETRAHYDRO 3 METHYL 2 OXO 6 QUINAZOLINYL)BENZENESULFONAMIDE; 4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; AZACITIDINE; BELINOSTAT; CARBOPLATIN; CISPLATIN; DECITABINE; ENTINOSTAT; ERLOTINIB; EXEMESTANE; GUADECITABINE; HISTONE DEACETYLASE INHIBITOR; HYDRALAZINE; IRINOTECAN; N PHTHALOYLTRYPTOPHAN; PACLITAXEL; PANOBINOSTAT; PINOMETOSTAT; REGORAFENIB; RESMINOSTAT; ROMIDEPSIN; TACEDINALINE; TAZEMETOSTAT; TOPOTECAN; TREPROSTINIL; TUBASTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; ZEBULARINE; ANTINEOPLASTIC AGENT; METHYLTRANSFERASE;

ACUTE MYELOID LEUKEMIA; BREAST CANCER; CANCER SURVIVAL; CHEMOSENSITIZATION; COLORECTAL CANCER; CPG ISLAND; CUTANEOUS T CELL LYMPHOMA; DNA METHYLATION; DRUG TARGETING; ENZYME INHIBITION; EPIGENETIC THERAPY; EPIGENETICS; GENE EXPRESSION; GENE SILENCING; GENE THERAPY; HISTONE MODIFICATION; HUMAN; LOW DRUG DOSE; MELANOMA; MYELODYSPLASTIC SYNDROME; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; PERIPHERAL T CELL LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHABDOID TUMOR; SOLID TUMOR; TREATMENT RESPONSE; UTERINE CERVIX CANCER; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG RESISTANCE; GENETIC EPIGENESIS; GENETICS; NEOPLASMS; PATHOLOGY; PROCEDURES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; GENETIC THERAPY; HISTONE DEACETYLASE INHIBITORS; HUMANS; METHYLTRANSFERASES; NEOPLASMS;

EID: 85017498386     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2017.03.008     Document Type: Review

References (53)

1. [1] Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
2. [2] Feinberg, A.P., Tycko, B., The history of cancer epigenetics. Nat Rev Cancer 4 (2004), 143–153.
3. [3] Dawson, M.A., Kouzarides, T., Cancer epigenetics: from mechanism to therapy. Cell 150 (2012), 12–27.
4. [4] Azad, N., Zahnow, C.A., Rudin, C.M., Baylin, S.B., The future of epigenetic therapy in solid tumours–lessons from the past. Nat Rev Clin Oncol 10 (2013), 256–266.
5. [5] Berger, S.L., Kouzarides, T., Shiekhattar, R., Shilatifard, A., An operational definition of epigenetics. Genes Dev 23 (2009), 781–783.
6. [6] Bojang, P. Jr., Ramos, K.S., The promise and failures of epigenetic therapies for cancer treatment. Cancer Treat Rev 40 (2014), 153–169.
7. [7] Baylin, S.B., Jones, P.A., A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 11 (2011), 726–734.
8. [8] Roy, D.M., Walsh, L.A., Chan, T.A., Driver mutations of cancer epigenomes. Protein Cell 5 (2014), 265–296.
9. [9] Ahuja, N., Sharma, A.R., Baylin, S.B., Epigenetic therapeutics: a new weapon in the war against cancer. Annu Rev Med 67 (2016), 73–89.
10. [10] van Kampen, J.G., Marijnissen-van Zanten, M.A., Simmer, F., van der Graaf, W.T., Ligtenberg, M.J., Nagtegaal, I.D., Epigenetic targeting in pancreatic cancer. Cancer Treat Rev 40 (2014), 656–664.
11. [11] Liu, F., Wang, L., Perna, F., Nimer, S.D., Beyond transcription factors: how oncogenic signalling reshapes the epigenetic landscape. Nat Rev Cancer 16 (2016), 359–372.
12. [12] Berger, S.L., The complex language of chromatin regulation during transcription. Nature 447 (2007), 407–412.
13. [13] Esteller, M., Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet, 2007, R50–R59 16 Spec No 1.
14. [14] Nervi, C., De Marinis, E., Codacci-Pisanelli, G., Epigenetic treatment of solid tumours: a review of clinical trials. Clin Epigenet, 7, 2015, 127.
15. [15] Jones, P.A., Baylin, S.B., The epigenomics of cancer. Cell 128 (2007), 683–692.
16. [16] Kaminskas, E., Farrell, A.T., Wang, Y.C., Sridhara, R., Pazdur, R., FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist 10 (2005), 176–182.
17. [17] Chiappinelli, K.B., Zahnow, C.A., Ahuja, N., Baylin, S.B., Combining epigenetic and immunotherapy to combat cancer. Can Res 76 (2016), 1683–1689.
18. [18] Bao, B., Wang, Z., Ali, S., Ahmad, A., Azmi, A.S., Sarkar, S.H., et al. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prevent Res 5 (2012), 355–364.
19. [19] West, A.C., Johnstone, R.W., New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 124 (2014), 30–39.
20. [20] Juergens, R.A., Wrangle, J., Vendetti, F.P., Murphy, S.C., Zhao, M., Coleman, B., et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 1 (2011), 598–607.
21. [21] Sandor, V., Senderowicz, A., Mertins, S., Sackett, D., Sausville, E., Blagosklonny, M.V., et al. P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer 83 (2000), 817–825.
22. [22] Bose, P., Dai, Y., Grant, S., Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol Ther 143 (2014), 323–336.
23. [23] Pauer, L.R., Olivares, J., Cunningham, C., Williams, A., Grove, W., Kraker, A., et al. Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Cancer Invest 22 (2004), 886–896.
24. [24] Undevia, S.D., Kindler, H.L., Janisch, L., Olson, S.C., Schilsky, R.L., Vogelzang, N.J., et al. A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 15 (2004), 1705–1711.
25. [25] Nemunaitis, J.J., Orr, D., Eager, R., Cunningham, C.C., Williams, A., Mennel, R., et al. Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer. Cancer J 9 (2003), 58–66.
26. [26] Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109 (2007), 31–39.
27. [27] VanderMolen, K.M., McCulloch, W., Pearce, C.J., Oberlies, N.H., Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J Antibiot (Tokyo) 64 (2011), 525–531.
28. [28] Baylin, S.B., DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2:Suppl. 1 (2005), S4–S11.
29. [29] Baylin, S.B., Schuebel, K.E., Genomic biology: the epigenomic era opens. Nature 448 (2007), 548–549.
30. [30] Ahuja, N., Easwaran, H., Baylin, S.B., Harnessing the potential of epigenetic therapy to target solid tumors. J Clin Invest 124 (2014), 56–63.
31. [31] Leu, Y.W., Yan, P.S., Fan, M., Jin, V.X., Liu, J.C., Curran, E.M., et al. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Can Res 64 (2004), 8184–8192.
32. [32] Hessmann, E., Johnsen, S.A., Siveke, J.T., Ellenrieder, V., Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?. Gut 66 (2017), 168–179.
33. [33] Adelaiye, R., Ciamporcero, E., Miles, K.M., Sotomayor, P., Bard, J., Tsompana, M., et al. Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications. Mol Cancer Ther 14 (2015), 513–522.
34. [34] Chavez-Blanco, A., Perez-Plasencia, C., Perez-Cardenas, E., Carrasco-Legleu, C., Rangel-Lopez, E., Segura-Pacheco, B., et al. Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int, 6, 2006, 2.
35. [35] Candelaria, M., Gallardo-Rincon, D., Arce, C., Cetina, L., Aguilar-Ponce, J.L., Arrieta, O., et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 18 (2007), 1529–1538.
36. [36] Coronel, J., Cetina, L., Pacheco, I., Trejo-Becerril, C., Gonzalez-Fierro, A., de la Cruz-Hernandez, E., et al. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. Med Oncol 28:Suppl. 1 (2011), S540–S546.
37. [37] Brock, M.V., Hooker, C.M., Ota-Machida, E., Han, Y., Guo, M., Ames, S., et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 358 (2008), 1118–1128.
38. [38] Witta, S.E., Jotte, R.M., Konduri, K., Neubauer, M.A., Spira, A.I., Ruxer, R.L., et al. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol: Off J Am Soc Clin Oncol 30 (2012), 2248–2255.
39. [39] Ramalingam, S.S., Maitland, M.L., Frankel, P., Argiris, A.E., Koczywas, M., Gitlitz, B., et al. Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol: Off J Am Soc Clin Oncol 28 (2010), 56–62.
40. [40] Yardley, D.A., Ismail-Khan, R.R., Melichar, B., Lichinitser, M., Munster, P.N., Klein, P.M., et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol: Off J Am Soc Clin Oncol 31 (2013), 2128–2135.
41. [41] Connolly, R., Li, H., Jankowitz, R.C., Zhang, Z., Rudek, M.A., Jeter, S.C., et al. Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. Clin Cancer Res: Off J Am Assoc Cancer Res, 2016, 1–11.
42. [42] Fu, S., Hu, W., Iyer, R., Kavanagh, J.J., Coleman, R.L., Levenback, C.F., et al. Phase 1b–2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 117 (2011), 1661–1669.
43. [43] Watanabe, Y., Ueda, H., Etoh, T., Koike, E., Fujinami, N., Mitsuhashi, A., et al. A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer. Anticancer Res 27 (2007), 1449–1452.
44. [44] Wei, S.H., Chen, C.M., Strathdee, G., Harnsomburana, J., Shyu, C.R., Rahmatpanah, F., et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res: Off J Am Assoc Cancer Res 8 (2002), 2246–2252.
45. [45] Matei, D., Fang, F., Shen, C., Schilder, J., Arnold, A., Zeng, Y., et al. Epigenetic resensitization to platinum in ovarian cancer. Can Res 72 (2012), 2197–2205.
46. [46] Medicine, J.H., Experimental drug guadecitabine found safe in patients with colorectal cancer: combination with standard chemotherapy shows promise in overcoming treatment resistance. Sci Daily, 2016.
47. [47] Chiappinelli, K.B., Strissel, P.L., Desrichard, A., Li, H., Henke, C., Akman, B., et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162 (2015), 974–986.
48. [48] Wrangle, J., Wang, W., Koch, A., Easwaran, H., Mohammad, H.P., Vendetti, F., et al. Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget 4 (2013), 2067–2079.
49. [49] Liu, M., Ohtani, H., Zhou, W., Orskov, A.D., Charlet, J., Zhang, Y.W., et al. Vitamin C increases viral mimicry induced by 5-aza-2′-deoxycytidine. Proc Natl Acad Sci USA 113 (2016), 10238–10244.
50. [50] Li, H., Chiappinelli, K.B., Guzzetta, A.A., Easwaran, H., Yen, R.W., Vatapalli, R., et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget 5 (2014), 587–598.
51. [51] Hulbert, A., Jusue Torres, I., Stark, A., Chen, C., Rodgers, K., Lee, B., et al. Early detection of lung cancer using DNA promoter hypermethylation in plasma and sputum. Clin Cancer Res: Off J Am Assoc Cancer Res, 2016, 1–8.
52. [52] Qi, W., Chan, H., Teng, L., Li, L., Chuai, S., Zhang, R., et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci USA 109 (2012), 21360–21365.
53. [53] Bitler, B.G., Aird, K.M., Garipov, A., Li, H., Amatangelo, M., Kossenkov, A.V., et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat Med 21 (2015), 231–238.